The metabolic score for insulin resistance in the prediction of major adverse cardiovascular events in patients after coronary artery bypass surgery: a multicenter retrospective cohort study

Table 4 Univariate Cox regression analyses for MACE

Variables	HR	HR95%CI	p-value
Male	0.86	0.66–1.13	0.288
Age	1.03	1.02–1.05	< 0.001
Previous MI	1.17	0.87–1.58	0.308
Previous stroke	1.32	0.96–1.84	0.092
Previous PCI	0.87	0.56–1.33	0.516
Admission for MI	0.82	0.59–1.16	0.262
Hypertension	1.27	0.97–1.66	0.086
DM	1.30	1.01–1.69	0.049
Hyperlipidemia	1.16	0.90–1.51	0.256
FH-CAD	0.95	0.70–1.31	0.770
LVEF	0.16	0.05–0.47	0.001
TC	1.22	1.12–1.33	< 0.001
eGFR	0.99	0.99–1.00	0.006
LDL-C	1.14	1.00–1.31	0.057
Antiplatelet drugs	0.88	0.28–2.74	0.820
Beta-blockers	0.46	0.33–0.63	< 0.001
Statins	1.20	0.85–1.68	0.303
ACEI/ARB	1.06	0.76–1.48	0.736
Hypoglycemic drugs	1.15	0.86–1.53	0.348
METS-IR	1.05	1.03–1.06	< 0.001
MEST-IR (Per SD)	1.36	1.20–1.54	< 0.001

MACE the major adverse cardiovascular events, HR hazard ratio, CI confidence interval, MI myocardial infarction, PCI percutaneous transluminal coronary intervention, DM diabetes mellitus, FH-CAD family history of coronary artery disease, LVEF left ventricle ejection fraction, TC total cholesterol, eGFR estimated glomerular filtration rate, LDL-C low-density lipoprotein-cholesterol, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, METS-IR the metabolic score for insulin resistance
p values in bold are < 0.05

ISSN: 1758-5996